(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2006 (18.05.2006)

PCT

(10) International Publication Number
WO 2006/053161 A1

(51) International Patent Classification:
A61K 31/495 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/US2005/040824

(22) International Filing Date:
9 November 2005 (09.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/626,154 9 November 2004 (09.11.2004) US

(71) Applicant *(for all designated States except US)*: **CV THERAPEUTICS, INC.** [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BLACKBURN, Brent** [US/US]; 633 Almond Avenue, Los Altos, CA 94022 (US). **SABBAH, Hani** [US/US]; 1141 Meadowood Drive, Waterford, MI 48327 (US).

(74) Agents: **HARTRUM, J., Elin** et al.; CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(48) Date of publication of this corrected version:
14 September 2006

[Continued on next page]

(54) Title: USE RANOLAZINE IN COMBINATION WITH AT LEAST ONE REMODELING AGENT FOR REVERSING LEFT VENTRICULAR REMODELING IN THE TREATMENT OF HEART FAILURE



(57) Abstract: The present invention relates to a method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

WO 2006/053161 A1

(15) Information about Correction:
see PCT Gazette No. 37/2006 of 14 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.